GlassScriptPhysician profile
Latosha Mollette
NPI 1821641374
$3,679.22
in general payments reported to CMS, 2019-2025
31 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,402 · 2022: $814 · 2023: $623 · 2024: $449 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.11 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $546.72 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $480.08 | 2021-2025 | |
| Novo Nordisk INC | $251.03 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $250.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $214.87 | 2021-2023 | Verquvo |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.93 | 2021-2022 | |
| Amgen INC. | $106.50 | 2021-2023 | Otezla, Repatha |
| Sumitomo Pharma America, INC. | $105.09 | 2024-2025 | Gemtesa, Myfembree |
| Advanced Respiratory, INC | $95.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $86.38 | 2021-2023 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $71.80 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.07 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $55.47 | 2021-2023 | Myrbetriq |
| Pfizer INC. | $52.24 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $51.10 | 2021-2022 | |
| Verona Pharma, INC. | $42.61 | 2025 | Ohtuvayre |
| Biodelivery Sciences International, INC. | $39.83 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.12 | 2022-2025 | Caplyta |
| Eisai INC. | $31.58 | 2021 | |
| Philips North America LLC | $29.54 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.19 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.02 | 2021 | |
| Ibsa Pharma INC. | $17.94 | 2024 | Tirosint, Licart |
| Amarin Pharma, INC. | $17.58 | 2021 | |
| Exact Sciences Corporation | $17.10 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $16.52 | 2025 | Auvelity |
| Smith+Nephew, INC. | $16.04 | 2022 | |
| Esperion Therapeutics, INC. | $14.28 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latosha Mollette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.